After a quick FDA approval in a subset of endometrial cancer, GSK is back with more data for two Jemperli regimens in hopes of reaching a broader patient population. And AstraZeneca, utilizing a ...
On July 31, GSK released its financial results for the second quarter of 2024, which again beat analysts' expectations by a wide margin. Under Emma Walmsley's leadership, the company is becoming a ...
Recent performance and why GSK stock is back on radar GSK (LSE:GSK) has quietly delivered a strong run this year, with the share price up about 34% year to date and roughly 44% over the past year, ...
A Reuters report regarding the rejection of Unilever's $68 billion offer for GlaxoSmithKline’s consumer healthcare assets is raising questions, including whether Unilever should raise the bid and risk ...
GSK has outperformed both the healthcare sector and S&P 500 this year, which is notable considering the spectre of high ...
(Reuters) – Unilever faces a dilemma after its 50 billion pound ($68 billion) offer for GlaxoSmithKline’s consumer healthcare assets was rejected — should it raise the bid and risk overpaying or seek ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...
GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline over ...
Experts question Pfizer's failure to inform pregnant women of safety signal in GSK RSV vaccine trial
A debate has broken out over whether Pfizer should have told pregnant women taking part in its maternal respiratory syncytial virus (RSV) vaccine trial that a trial of a similar GSK vaccine was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback